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Abstract Due to the heterogeneous nature of breast
cancer and the widespread use of single-gene studies, there
is limited knowledge of multi-gene, locus-specific DNA
methylation patterns in relation to molecular subtype and
clinical features. We, therefore, quantified DNA methyla-
tion of 70 candidate gene loci in 140 breast tumors and
matched normal tissues and determined associations with
gene expression and tumor subtype. Using Sequenom’s
EpiTYPER platform, approximately 1,200 CpGs were
interrogated and revealed six DNA methylation patterns in
breast tumors relative to matched normal tissue. Differen-
tial methylation of several gene loci was observed within
all molecular subtypes, while other patterns were subtype-
dependent. Methylation of numerous gene loci was inver-
sely correlated with gene expression, and in some cases,
this correlation was only observed within specific breast
tumor subtypes. Our findings were validated on a larger set
of tumors and matched adjacent normal tissue from The
Cancer Genome Atlas dataset, which utilized methylation
data derived from both Illumina Infinium 27 and 450 k
arrays. These findings highlight the need to control for
subtype when interpreting DNA methylation results, and
the importance of interrogating multiple CpGs across var-
ied gene regions.
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Abbreviations
TCGA The Cancer Genome Atlas
MP Methylation pattern
UNC University of North Carolina
GEO Gene expression omnibus
NaBi Sodium bisulfite
HCA Hierarchical clustering analysis
SD Subtype-dependent
SI Subtype-independent
HypoB Hypomethylated in basal tumors
HyperN Hypermethylated in normals
HypoN Hypomethylated in normals
DMinNB Differentially methylated in non-basal tumors
InfreqM Infrequently methylated
NotDM Not differentially methylated
Introduction
Breast cancer is one of the most prevalent and well-studied
forms of cancer. Despite abundant research, knowledge of
the molecular basis of breast cancer subtypes is still
incomplete, due in large part to the heterogeneous nature of
the disease. Aberrant patterns of DNA methylation are
consistently observed in human cancers [1, 5, 7], and
increasing attention is being placed on the varied roles
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DNA methylation can play in gene expression regulation
and DNA–protein interactions [9, 10, 25].
Much of the progress that has been made in the char-
acterization of altered DNA methylation patterns in breast
cancer has used a candidate-gene approach, and has con-
sistently shown numerous methylated genes in breast
cancer cell lines and tumors such as RASSF1, RARB,
ESR1, BRCA1, CCND2, and CDKN2A [2, 8, 20].
Recently, ‘‘genome-wide’’ methylation studies have found
DNA methylation patterns associated with molecular sub-
types of breast cancer; namely lower overall levels of
methylation in basal-like tumors, and higher levels of
methylation in a subset of luminal B tumors [3, 12]. A
sizeable number of these observed methylated loci have
also been shown to be associated with decreased gene
expression [2, 19, 22, 23].
The Cancer Genome Atlas (TCGA) breast consortium
(2012) reported five methylation groups defined by breast
tumor sample clustering; groups 1–4 were enriched for
ER?, PR? tumors, while group 5 had the lowest levels of
methylation and was enriched for triple-negative, basal-like
tumors. Group 3 tumors had the highest levels of methyl-
ation and were enriched for the luminal B subtype [3].
Nevertheless, each of the five methylation groups described
by the TCGA were represented by an admixture of multiple
tumor subtypes. Overall, previous studies have had limited
descriptions of methylation patterns and their relation to
subtype, and few have explored the similarities and dif-
ferences between methylation patterns at different loci in
relation to methylation in matched normal breast tissues.
Therefore, the purpose of this study was to quantify
DNA methylation in a set of 70 candidate genes from
n = 140 breast tumors and matched normal tissues, and to
test associations with gene expression, and breast tumor
subtype (e.g., Basal-like, HER2-enriched, Luminal A and
B tumors). In parallel, we also sought to determine if two
different detection assays, Sequenom’s EpiTYPER Mass-
ARRAY and the Illumina Infinium platforms, provided
comparable methylation values for identical CG loci. In
contrast with the approach used to define methylation
groups by the TCGA consortium, we a priori stratified our
methylation analyses based on PAM50 subtype calls from
Agilent microarrays previously run in the UNC tumors.
Subsequently, we statistically validated our findings in the
TCGA dataset by molecular subtype. We took care to
insure that our validation in the TCGA dataset was as
equivalent as possible to the UNC dataset by only ana-
lyzing those TCGA samples for which Agilent microarray
data were used to determine relative gene expression and to
make the PAM50 calls.
We observed six distinct patterns of DNA methylation
within our candidate gene loci in breast tumors relative to
molecular subtype and matched normal tissue. These
methylation patterns (MPs) have unique distributions,
either by virtue of tumor subtype, and/or their level of
methylation in matched normal breast tissue. Methylation
patterns interrogated by MassARRAY in the UNC dataset
were validated in matched CGs in tumor and normal breast
tissues obtained from TCGA using the Illumina Infinium
platform. Many of the gene loci analyzed were inversely
associated with gene expression in breast tumors, and often
novel or stronger correlations were observed when the data
were stratified by molecular subtype. Importantly, corre-
lations of methylation with gene expression were inde-
pendent of methylation pattern group membership. These
results may help to further our understanding of the genetic
and epigenetic contributions to breast cancer heterogeneity.
Methods
UNC sample and previous gene expression data accrual
University of North Carolina (UNC) breast tissue samples
consisted of n = 140 specimens, n = 83 tumors, and
n = 57 paired normal breast tissues, collected in accor-
dance with Biomedical Institutional Review Board
approval through the UNC Office of Human Research
Ethics. All breast tissues for this methylation study were
collected from fresh frozen samples. All tumors had greater
than 50 % tumor cells, and on average 70 % tumor epi-
thelium, as determined by pathological/histological ana-
lysis. Adjacent matched normal tissues from the ipsilateral
breast were processed in the same manner as the tumors.
Additionally, oligonucleotide gene expression micro-
arrays (Agilent Technologies, Santa Clara, CA, USA) [13]
had previously been performed on these samples prior to
this study and deposited in the Gene Expression Omnibus
(GEO) under the accession number GSE35629. The
PAM50 algorithm [15] was used to assign molecular sub-
types of n = 83 breast tumors, consisting of 29 % Luminal
A, 28 % Luminal B, 27 % Basal-like, 12 % HER2-enri-
ched, and 2 % Normal-like, as previously described [15].
The two Normal-like tumors were excluded from all sub-
sequent analyses. Clinical and demographic data, PAM50
molecular subtypes, and GEO accession numbers for the
UNC sample set are listed in Online Resource 1.
Finally, Lowess normalized log2 ratios (Cy5 sample/
Cy3 control) of the 70 genes interrogated for methylation
in this study were median-centered prior to generating
relative gene expression values. Multiple probes for the
same gene were collapsed by averaging before median-
centering. Subsequently, gene expression values were
correlated with percent methylation values for the CpG
units interrogated on the MassARRAY platform
(Table 1, 2).
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Candidate gene selection
The candidate genes selected for this study were carefully
chosen due to their pivotal roles in cancer biology in gen-
eral, and/or because they represent PAM50 genes such as
MIA, PHGDH, KRT5, GRB7, EGFR, and CDH3. For
example, we chose to interrogate methylation in ‘‘BRCA1
related’’ genes (such as BRCA1 and BRCA2), genes
involved in epithelial–mesenchymal transition (such as
VIM, TWIST, and CDH1), genes which direct methylation
metabolism or histone modifications (such as DNMT3b and
HDAC9), or genes that previous studies have repeatedly
identified as being significantly methylated in breast cancer
(such as RASSF1, APC, CCND2, PTEN, and RARB).
DNA extraction and sodium bisulfite conversion
DNA extraction was performed on the UNC n = 140
sample set using either the Qiagen Puregene Core Kit A
or the Qiagen DNAeasy Blood & Tissue Kit (Qiagen,
Germantown, MD, USA). Sodium bisulfite (NaBi) con-
version of genomic DNA extracted from breast tissue was
carried out using the EZ DNA Methylation-Direct Kit
(Zymo Research, Irvine,CA, USA) as previously described
[21].
Quantification of DNA methylation using mass
spectrometry
Mass spectrometry was used to quantify percent methyla-
tion for 70 candidate gene loci on the SEQUENOM
MassARRAY platform using the EpiTYPER T complete
reagent kit as previously described [21]. Custom primers
were designed for amplicons representing 70 genes with a
total coverage of approximately 1,200 CGs. PCR was
carried out on 5–10 ng of NaBi-converted DNA using
NaBi conversion specific primers (Online Resource 2), in
5 ll volumes with PCR conditions as previously described
[21]. As per the EpiTYPER protocol, shrimp alkaline
phosphatase was used to dephosphorylate unincorporated
dNTPs. Finally, RNase-A was added in the T-cleavage
reaction, rendering methylated and unmethylated CG
containing fragments subsequently quantified by mass
spectrometry.
The EpiTYPER software identifies methylated versus
unmethylated CGs based on detection of a 16-Dalton mass
shift between the two peaks. The software then calculates
the percent methylation based on the relative ratio of
methylated to unmethylated CGs within a margin of 5 %
methylation confidence interval [4, 6, 16]. In some cases,
fragments resulting from the T-cleavage reaction may
contain more than one CpG dinucleotide, and are thus
referred to as ‘‘CpG units.’’ Percent methylation of such
CpG units are calculated as previously described [4]. Some
values for CpG containing fragments fall near or outside
the 1,000–8,000 Dalton window in which the MassArray
platform performs accurate percent methylation, and thus
calculations are assigned an ‘‘N/A’’ as these values cannot
be quantified reliably.
Hierarchical clustering in the UNC tumor set
Nucleic acids derived from the UNC tumors and matched
normal breast tissues had previously been used for separate
molecular studies, including the gene expression analysis
described below. Therefore, there was limited DNA
remaining from the n = 81 UNC tumor dataset to perform
the methylation assays. The result was that we were able to
quantify methylation for 33 gene loci in 81 tumors (UNC
set A), and an additional 37 genes in a subset of 53 of the
81 tumors (UNC set B). As complete data are needed for
clustering analysis, we performed unsupervised hierarchi-
cal clustering (HCA) separately on these two distinct gene/
tumor sets (Online Resource 3). HCA of MassARRAY
methylation data in the UNC tumor/matched normal
dataset, followed by validation of methylation patterns in
TCGA tumors and matched normal tissues revealed the six
methylation patterns described herein.
Independent validation in TCGA breast tumor
and normal samples
Methylation and gene expression data accession
from TCGA
The MassARRAY methylation findings from the UNC
study of breast cancer patients were compared with a
publically available, open-access dataset of invasive breast
adenocarcinoma from The Cancer Genome Atlas (TCGA).
Each tumor and adjacent normal tissue specimen (if
available) was embedded and a histologic section was
obtained for review. A board-certified pathologist reviewed
each H&E-stained case to confirm that the tumor specimen
was histologically consistent with breast adenocarcinoma
and the adjacent normal specimen contained no tumor
cells, in accordance with TCGA protocol requirements [3].
DNA methylation data were generated using the Illumina
Infinium Meth27K or Meth450K platform and presented as
b values, with 0 indicating 0 % DNA methylation and b
values of 1 indicating 100 % DNA methylation. Methyla-
tion data from 21,986 CpG sites from 813 breast tumors
and 123 adjacent non-tumor breast tissue samples was
obtained from the TCGA Data Portal (https://tcga-data.nci.
nih.gov/docs/publications/brca_2012/) in the file BRCA.
methylation.27k.450k.zip (Data freeze: November 11,
Breast Cancer Res Treat (2013) 142:365–380 367
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2011). In order to insure equivalent comparisons between
UNC and TCGA samples, only those tumors with PAM50
subtype calls from Agilent arrays were utilized for this
study, leaving 455 tumor tissue samples and 70 matched
normal samples (Online Resources 4 and 5).
Inclusion of data for specific CpG sites were chosen
based on proximity to the CpG units that were interrogated
by MassArray. Data for CpG sites with direct matches with
MassArray amplicons were included in the dataset, and are
labeled in Tables 1 and 2 by the CpG unit they correspond
to in the MassArray amplicon. If there was no direct match
for the CpG unit in the TCGA dataset, then CpG sites
closest to the MassArray amplicon were included, with the
base pair distance from the MassArray amplicon listed in
Table 2.
Statistical analyses
Unsupervised hierarchical clustering based on complete
linkage and Euclidean distance of percent methylation
values in the UNC dataset was performed and displayed
using MeV (version 4.8.1) of the TM4 software suite [17]
(Fig. 1a–d). Relative gene expression in both UNC and
TCGA sample sets was measured by normalized log2 ratios
(Cy5 sample/Cy3 control) for each of the 70 genes inter-
rogated in this study. In the cases where there were multiple
probes per gene, log2 values were averaged. The Pearson r
statistic was used to correlate relative gene expression and
percent methylation in the UNC dataset, and by Illumina b
methylation values in the TCGA dataset (Tables 1, 2).
Pearson correlation values greater than (? or -0.2) with a
p value equal or less than 0.05 were considered significantly
correlated. In order to validate each of the six unique
methylation pattern features observed in the UNC tumor/
matched normal pairs, ANOVA was used to assess differ-
ences in mean percent methylation or b values in the UNC
and TCGA datasets, respectively (Figs. 2, 3, 4, 5, 6).
Finally, R (http://www.R-project.org) was used to plot the
contributors to significant inverse correlations of methyla-
tion with gene expression (Figs. 7, 8).
Results
Unsupervised clustering of methylation data reveals
distinct methylation patterns in breast cancer subtypes
Unsupervised hierarchical clustering of DNA methylation
data within candidate gene loci was performed on the two
UNC datasets and revealed six distinct methylation pat-
terns relative to breast cancer subtype and matched normal
breast tissues. Consensus clustering was not possible when
attempting to validate methylation patterns in the TCGA
dataset due to a lack of equivalence between methylated
loci in the UNC and TCGA samples. The methylation data
used for this validation study were derived from both 27
and 450 k Illumina Infinium platforms that, once normal-
ized and filtered by the TCGA investigators, resulted in
methylation data for only *22,000 probes covering the
entire human genome (BRCA.methylation.27k.450k.zip)
[3]. Therefore, this publically available methylation data
file had far fewer methylation probes than the *480,000
CG sequences originally interrogated. We were, therefore,
fortunate to have been able to match 61 (see Online
Resource 6), corresponding Illumina CG probes in the
published TCGA dataset relative to the 1,200 CGs inter-
rogated in the UNC dataset. Specifically, MassARRAY is
more of a fine mapping platform which allows interroga-
tion of many consecutive CpG sequences within a single
amplicon, while the Illumina platform has a ‘‘genome
wide’’ application, and consequently interrogates fewer
CpGs per gene. Using the available TCGA methylation
data described, observed methylation patterns were statis-
tically validated in the TCGA by hypothesis testing of each
of six unique pattern features.
Methylation pattern 1 (MP1) gene loci were subtype-
dependent (SD) and characterized by a subset of relatively
hypomethylated basal-like tumors ‘‘SD-HypoB.’’ This
group included MIA, KRT17, and KRT5, (Fig. 1b,d) which
were hypermethylated in all normal tissues and tumor
subtypes, except for a subset of basal-like tumors that were
relatively hypomethylated as exemplified by MIA (Fig. 2).
MP2 gene loci such as SFN, SERPINB5, and DIRAS3
(Fig. 1a,c) were differentially methylated across all sub-
types, and thus methylation patterns were subtype-inde-
pendent (SI). In addition, MP2 loci were differentially
methylated in tumors, had high methylation levels in nor-
mal tissue that typically ranged from 30 to 60 % (Fig. 3),
and, therefore, were referred to as ‘‘SI-HyperN.’’ Differ-
ential methylation for MP3 gene loci such as GRB7, TCF4,
MGMT, TWIST, and TERT was also independent of
subtype; however, this pattern was distinguished by hy-
pomethylation in matched normal tissues, in contrast to the
hypermethylation in normal tissues observed at MP2 loci
(Fig. 4). Therefore, we describe MP3 loci as ‘‘SI-HypoN’’
(Fig. 4).
MP4 gene loci were hypomethylated in the majority of
basal-like tumors, and differentially methylated across non-
basal-like subtypes (e.g., HER2-enriched and Luminal A
and B tumors), with relative hypomethylation in matched
normal breast tissue (Figs. 1a–c, 5). Therefore, these sub-
type-dependent, differentially methylated in non-basal-like
tumor loci were designated as ‘‘SD-DMinNB.’’ MP5 genes
such as PHGDH, PGR, CDKN2A, RARB, and BRCA1
were infrequently methylated at the loci interrogated,
reaching a level of 20 % methylation or higher in fewer
368 Breast Cancer Res Treat (2013) 142:365–380
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than 15 % of all tumor samples (Figs. 1a,b, 6). These
subtype-dependent, infrequently methylated loci (desig-
nated SD-InfreqM) were hypomethylated in matched nor-
mal breast tissues. Finally, MP6 gene loci were not
differentially methylated (NotDM), and, therefore, unin-
formative (Fig. 1a–d). Thus MP6 loci were excluded from
further analyses (see Online Resource 2).
Correlations between gene expression and DNA
methylation are concordant between MassARRAY
and Illumina platforms and vary by breast cancer
subtype
Many of the amplicons analyzed in the UNC dataset
showed significant inverse correlations between DNA
Fig. 1 a–d Unsupervised hierarchical clustering analysis of candi-
date loci methylation in UNC datasets identifies six methylation
patterns. The clustergram is highlighted on the left to display the
major clada for each dataset. The colored bar on the right of the
clustergram displays the methylation pattern group for either each
CpG unit or average methylation per gene (MP1 = yellow,
MP2 = dark blue, MP3 = light blue, MP4 = orange, MP5 = pur-
ple, and MP6 = green). Hierarchical clustering analysis (HCA) by
CpG unit of a 81 tumors and b 53 tumors reveal enrichment of
methylation patterns for each cluster. HCA of averaged methylation
per locus for c 81 tumors and 33 genes and d 53 tumors and 37 genes
show similar clustering groups and methylation patterns compared to
clustergrams based on individual CpG units. See online resource 3 for
a detailed listing of rows (genes, CpG IDs) and columns (tumor
subytpe)
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Fig. 2 a–d MP1 gene loci display hypermethylation in normal tissue
and all tumor subtypes with a subset of basal tumors displaying a
hypomethylated phenotype. Box plots display percent methylation
distributions in normal breast tissue and matched tumors (n = 57
matched pairs for the UNC dataset and n = 70 matched pairs for the
TCGA dataset) where the upper and lower whiskers represent 1.5
times the interquartile range (IQR). Molecular subtype is listed on the
horizontal axis and percent methylation on the vertical axis. Each dot
represents the average percent methylation by MassARRAY across
the amplicon for the UNC dataset, or for the b values of the closest
MIA Illumina probe (cg25152942) in the TCGA dataset, respectively.
Tumors are grouped by PAM50 molecular subtypes assigned from
previous oligoarray analysis (Basal = red, HER2-enriched = pink,
Luminal A = dark blue, and Luminal B = light blue), while normal
tissues are grouped by the molecular subtype of the matched tumor.
The MP1 ‘‘SD-HypoB’’ locus pattern was recapitulated in TCGA
breast samples by t test of methylation differences between basal and
non-basal tumors significant for tumors in both a the UNC dataset and
b the TCGA dataset, while no significant difference was observed in
matched normal tissue in either dataset. MIA methylation in c UNC
breast tumors and matched normal tissue and d TCGA breast tumors
and matched normal tissue are displayed in scatterplots. (Note: similar
or overlapping percent methylation values for each CpG within an
amplicon by MassARRAY will appear as one ‘‘dot’’ in the UNC
scatterplots). T test p values for the basal vs. non-basal test are
provided in the bottom right of each figure
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methylation and gene expression (Table 1). Each CpG unit
was correlated with the log2 gene expression value;
therefore, correlations are displayed from a low–high
range, as well as an overall correlation based on average
methylation over the entire amplicon. While the UNC
dataset was not large enough to examine correlations of
DNA methylation and gene expression by subtype, the
TCGA dataset was large enough to enable stratified ana-
lysis. Many of the CpG units analyzed revealed varying
correlations between DNA methylation and gene expres-
sion that were subtype-dependent, including MIA, DAPK1,
KLK10, BRCA1, and PHGDH (Table 2).
With few exceptions, methylation correlations with gene
expression in the UNC dataset were comparable to corre-
sponding IIlumina probes from TCGA, particularly for
those gene loci having the least variable methylation
throughout the amplicon (Table 1). Low methylation var-
iability for all CGs interrogated within an amplicon is
evidenced by concordance of average, low, and high range
significant Pearson r and p values listed in Table 1, and by
clustering of CGs within the same gene locus (Fig. 1a,b).
We also observed several loci in normal tissues with sig-
nificant correlations (Table 2).
To investigate the major contributors to significant
correlations, we plotted methylation by log2 expression
values for several genes in TCGA tumors and matched
normal pairs (Fig. 7). Figure 7a demonstrates that the
subset of hypomethylated basal-like tumors at the MP1
MIA locus drives the significant correlation in tumors.
Notably, when the subset of basal-like tumors with
methylation b\ 0.5 were removed, the correlation was
no longer significant. Likewise, when the six high
methylation outlier matched normal samples from Lumi-
nal A tumors were removed, MIA methylation was no
longer correlated with the gene expression in normal
tissues (data not shown). Additionally, these plots show
Fig. 3 a–d MP2 gene loci display subtype-independent differential
methylation pattern with tumors exhibiting lower methylation com-
pared to normal tissue. SERPINB5 methylation in a UNC breast
tumors and matched normal tissue and b TCGA breast tumors and
matched normal tissue are displayed in scatterplots of individual CpG
units in the UNC dataset, and by b values for matched SERPINB5
probe cg20837735. MP2 ‘‘SI-HyperN’’ gene loci display significantly
lower average percent methylation in tumor samples vs. matched
normal tissue in both the c UNC dataset and were recapitulated in
d the TCGA dataset. T test p values for methylation differences
between tumor vs. normal samples are provided in the top right of
each box plot
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that the non-basal-like tumors for GSTP1, the basal-like
tumors for BRCA1, and the Luminal B tumors for
PHGDH drive the respective significant correlations at
these loci.
Discordant correlations between the UNC and TCGA
datasets include KRT5, EREG, and HDAC9, all loci with
variable CpG methylation across the amplicon. For
example, KRT5 did not achieve significance after
hypothesis testing of the MP1 pattern because the matched
probe available corresponded only to the highly variable
CpG 20.21 in the MassARRAY amplicon (Fig. 8). Exam-
ination of each KRT5 CpG interrogated by EpiTYPER
show KRT5_CpG6 is significant for the MP1 pattern
(Fig. 8a–c), while CpG 20.21 is not. In this case, the Illu-
mina platform was not truly discordant, but rather faithfully
reflects the variable methylation at this specific CpG.
Discussion
We studied the DNA methylation of 70 amplicons in 81
breast tumors and describe six locus-specific methylation
patterns in relation to tumor subtype and matched normal
breast tissues. These patterns were successfully validated in
a larger TCGA dataset of n = 455 tumors and n = 70
matched normal breast tissues. We found that differential
methylation was either subtype-dependent or subtype-
independent (e.g., differential methylation occurs in all
subtypes). For example, methylation patterns (MP) 1, MP4,
and MP5 are differentially methylated in a subtype-
dependent manner, whereas MP2 and MP3 loci were dif-
ferentially methylated across all subtypes.
Importantly, methylation is CpG locus-dependent and
may vary greatly over short bp distances as exemplified by
Fig. 4 a–d MP3 gene loci display subtype-independent differential
methylation with tumors exhibiting higher methylation compared to
normal tissue. MP3 gene loci are distinguished from MP2 loci by
relative hypomethylation in matched normal tissues, which are
subtype-independent; e.g., ‘‘SI-HypoN.’’ TCF4 methylation patterns
for a UNC breast tumors and matched normal tissue and b TCGA
breast tumors and matched normal tissue are displayed in scatterplots
of individual CpG units in the UNC dataset, and by b values for
matched TCF4 Illumina probe cg08491964. MP3 ‘‘SI-HypoN’’ gene
loci display significantly higher average percent methylation in
tumors compared to matched normal tissue in both the c UNC dataset
and d the TCGA datasets. T test p values for methylation differences
between tumor vs. normal samples are provided in the top right of
each box plot
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Fig. 5 a–d MP4 gene loci display a hypomethylated phenotype in
basal tumors and differential methylation in non-basal HER2, LumA,
and LumB tumors. Box plots show percent methylation distributions
in normal breast tissue and matched breast tumors. MP4, subtype-
dependent, differentially methylated in non-basal tumors ‘‘SD-
DMinNB’’ patterns were validated in the TCGA tumor and matched
normal sample set. A significant difference by ANOVA was observed
in average percent methylation of GSTP1 between molecular subtypes
in both a the UNC tumor dataset and b the TCGA tumor dataset for
the matched GSTP1 cg04920951 probe, while no significant
difference was observed in matched normal tissue in either dataset.
APC also demonstrated an MP4 methylation locus pattern, but unlike
GSTP1, APC methylation was not associated with gene expression in
either the c UNC or d TCGA dataset. (Boxplots shown are of averaged
percent methylation across the MassARRAY amplicon in the UNC
samples, and averaged b values for three matched APC probes;
cg21634602, cg20311501, and cg16970232, respectively). ANOVA
p values for testing methylation differences between molecular
subtype are provided in the top right of each box plot
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the KRT5 amplicon (Fig. 8). For this reason, not all CpG
units within the same amplicon cluster together, and can
segregate as ‘‘outlier’’ CpGs such as MGMT_001_7.8.9,
CST6_001_10, and HDAC9_001_1 (Online Resource 3).
Conversely, other loci such as MIA and VIM are more
homogeneously methylated over longer distances. For
example, the closest corresponding MIA and VIM CG
Illumina probes were *250 bp away from the EpiTyper
amplicon, yet these validation probes nevertheless had
highly similar methylation values with interrogated CpGs
in the UNC dataset, despite their distance from the target
CpG of measure (Tables 1, 2). Thus, the specific CpG
locus is critically important in any comparison between
methylation platforms, and in correlative analyses with
gene expression. Overall, Illumina CG probes having direct
matches with interrogated MassArray CGs were highly
comparable. While the Illumina platform provides good
genome-wide coverage for most genes, the EpiTYPER
MassARRAY platform has the distinct advantage of
quantifying an average 15–40 consecutive CpGs per
amplicon, thereby enabling the identification of highly
heterogeneous and informative loci that might otherwise go
undetected.
Historically, DNA methylation has been considered
noteworthy when associated with changes in gene expres-
sion. Indeed, the TCGA consortium identified 490 meth-
ylated genes inversely correlated with gene expression in
their Group 3 breast tumors, samples populated with hy-
permethylated genes and enriched for luminal B tumors
[3]. Of particular interest is our finding that multiple
methylation patterns were represented within the TCGA
Group 3 tumors such as MIA, DIRAS3, and GSTP1, loci
with MP1 (SD-HypoB), MP2 (SI-HyperN), and MP4 (SD-
DMinNB) patterns, respectively. We also found the MIA
and GSTP1 loci, (but not the DIRAS3 locus), reported by
the TCGA consortium were associated with gene expres-
sion. Moreover, our analyses relative to subtype and mat-
ched normal tissue (Table 2) allowed us to identify specific
contributors to significant correlations. For example, the
subset of hypomethylated basal-like tumors for MIA and
the non-basal-like tumors for the GSTP1 loci, respectively,
drive the significant inverse correlations of methylation
with gene expression (Fig. 7). When identified contributors
were removed from the analyses, including the six outlier
luminal A matched normal samples for KRT5, MIA, SFN,
and CST6, all correlations became insignificant. High
methylation/low expression findings in outlier matched
normal breast may have been due to field effects in these
six samples.
Distinct methylation patterns may or may not be
associated with gene expression as exemplified by MP4
loci GSTP1 and APC (Fig. 5). Overall, methylation of
many CpGs was associated with lower log2 expression
levels (e.g., BRCA1 and GSTP1); however, we also
observed the reverse at the MIA locus; e.g., lower
methylation was associated with higher gene expression
(Fig. 7). As proof of principle, we were encouraged that
correlation plots of gene expression and methylation
(Table 2; Fig. 7) confirmed past studies showing that
BRCA1 methylation is associated with decreased gene
expression [14, 24], and preferentially methylated in ER-
negative and basal-like breast cancer [11, 18]. Whereas
previous studies have used DNA methylation data to
cluster breast tumor samples with similar DNA methyla-
tion patterns, here we utilized methylation data to identify
and describe gene loci that have distinct patterns of
methylation between the four subtypes of breast tumors
and normal tissues.
In summary, percent methylation values obtained from
MassARRAY in the UNC dataset were recapitulated in the
TCGA using the Illumina Infinium platform, as were
methylation patterns MP1–MP6. Importantly, MP1–MP6
were revealed when comparing CG specific methylation in
both tumors and matched normal breast tissues, and when
stratifying methylation by PAM50 tumor subtype.
Depending on the locus, methylated loci may or may not be
correlated with gene expression, regardless of membership
within a particular methylation pattern. Moreover, meth-
ylation can be exquisitely locus specific and may vary
greatly within short base pair distances. We describe six
methylation patterns (MPs) found within our candidate
Fig. 6 a–h MP5 gene loci display subtype-dependent methylation
patterns with infrequent methylation. MP5 loci were subtype-depen-
dent and infrequently methylated ‘‘SD-InfreqM.’’ Only two tumors
were methylated at the BRCA1 locus in the UNC samples and no
significant differences were observed by ANOVA between molecular
subtypes in a UNC tumors and matched normal breast tissues, with
percent CpG methylation values averaged for the entire amplicon.
Frequency of methylation is displayed in a scatterplot of b the entire
UNC dataset (n = 81 tumors), where each CpG unit in the amplicon
is plotted. (Note: similar or overlapping percent methylation values
for each CpG within an amplicon by MassARRAY will appear as one
dot in the UNC scatterplots). A significant difference was observed in
b values for the BRCA1-matched cg08993267 Illumina probe
between molecular subtypes in the c TCGA-matched tumor normal
dataset (sample size n = 70). Frequency of methylation is displayed
in a scatterplot of d the entire TCGA dataset (n = 455 tumors). A
significant difference in percent methylation was observed in PHGDH
between molecular subtypes in e the UNC dataset and recapitulated in
g the TCGA dataset (PHGDH probe cg26791905). Methylation
frequency is displayed in scatterplot; f the entire UNC tumor dataset
and h the entire TCGA tumor dataset. ANOVA p values for testing
methylation differences between molecular subtypes is provided in
the top right of each boxplot
b
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Fig. 7 a–d Plotting
contributors of significant
inverse correlations with gene
expression. Methylation beta
values were plotted against
mRNA (logbase2 normalized
values) in the TCGA dataset,
with each data point
representing a tumor (n = 455
tumors). Tumor subtype is
displayed by the color of each
data point (Basal = red, HER2-
enriched = pink, Luminal
A = dark blue, and Luminal
B = light blue). a MIA
methylation correlation with
gene expression in tumors is
driven by the subset of basal
tumors with methylation b
values \ 0.5, and by the six
outlier Lumina A matched
normal samples. When both the
relatively hypomethylated
subset of basal tumors and
outlier normal samples were
removed, correlations were no
longer significant. b GSTP1 also
displayed significant overall
correlation between methylation
and gene expression as well as
significant correlations in all
subtypes except Basal tumors.
c BRCA1 overall correlation
between methylation and gene
expression was driven mainly
by Basal and Luminal B tumors.
d PHGDH overall correlation
was driven by the significant
correlation in Luminal B tumors
376 Breast Cancer Res Treat (2013) 142:365–380
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loci; however, future studies of other loci are likely to yield
additional, distinctive patterns by breast cancer subtype.
Further investigations of the variable frequency of the
methylation patterns described herein, together with their
contributions to altered gene expression, may ultimately
shed light on their role as passengers or drivers of
carcinogenesis. Given the contributions of MIA, KRT5,
KRT17, and PHGDH in defining the PAM50 basal-like
subtype, future studies will explore the mechanisms by
which these differentially methylated loci are associated
with altered gene expression, and the impact such changes
may have on breast cancer progression and prognosis.
Fig. 8 a–e The KRT5 interrogated locus shows high methylation
variability. MassARRAY methylation data for the KRT5 gene locus
in UNC tumors reveals heterogeneity throughout the 439-bp ampli-
con. a CpG number 6 in the KRT5 amplicon was significantly
(p = 0.04) differentially methylated by ANOVA between tumor
subtypes in the UNC samples, but did not have a direct probe match
in the TCGA dataset. b CpG unit 20.21 was not differently
methylated by ANOVA in the UNC samples, yet was the only CpG
unit for which the corresponding c TCGA KRT5 Illumina probe
cg04254916 was available. The non-significant ANOVA finding at
KRT CpG_20.21 was confirmed in the TCGA (e.g., ANOVA was not
significant in either the UNC or TCGA samples at this specific CpG
unit). To further illustrate the heterogeneity observed in the KRT5
amplicon, d correlation analysis between individual CpGs and gene
expression reveal CpGs as close as 23 bp apart have strikingly
different correlation values. While many CpGs in the amplicon were
significantly inversely correlated to gene expression, several CpGs
were not, including CpG 20.21, which is consistent with e the
matching TCGA probe not significantly associated with gene
expression.  Values for CpG fragments falling near or outside the
mass Dalton detection window cannot be reliably quantified and are,
therefore, excluded by the MassARRAY Epityper analytical software.
These include KRT5 CpGs 1, 3, 4, 5, 11, 12, 14, 15, 17, 18, 19, and
22. * Significant correlation between methylation and gene expres-
sion by individual CG
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